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In order to provide optimal cancer care and prognostication, it is necessary to stage the disease. The 8th
edition of the TNM-staging for exocrine pancreatic ductal adenocarcinoma (PDAC) system has refined
size-based T-stages and number-based N-categories. However, several impediments to the value of this
may exist. For one, even at small size (e.g. <0.5 cm), PDACs readily metastasize, making size unreliable to
predict behavior. The increasing shift towards neoadjuvant treatments for both resectable and borderline
PDAC, and use of conversion therapy for locally advanced disease, suggest the need for additional bio-
logical predictors. Here we discuss whether recent changes in the TNM system for PDAC are along the
lines of changes seen in contemporary management. Also, with the particular aggressive biology seen in
PDAC, it is questioned whether the minute details in TNM refinement represents true progress or merely
shuffles the cards.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Despite progress achieved in recent years, the survival for
pancreatic ductal adenocarcinoma (PDAC) remains poor; with a
mere 7e9% true survivors 5 years after diagnosis. Surgical resection
remains the only curative approach, with multimodal therapies
improving outcomes [1,2]. To accurately predict prognosis and
decide appropriate treatment options, it is vital to describe the
extent of the disease. Localized tumors have a higher survival rate
compared with disseminated disease. In addition, prognostication
directs the inclusion of patients in clinical studies and allows
comparison of care between institutions and registries. The strati-
fication into the correct prognostic stage group is therefore
important. However, with the changes in management and the
particular aggressive biology seen in PDAC, it is questionedwhether
such refinement represents true progress or merely shuffles the
cards.tinal Surgery, Stavanger Uni-
ier Ltd. This is an open access articRevisions in the TNM staging system
The tumor, node and metastasis (TNM) staging system is
regarded the most useful cancer staging system. There were no
changes made in the 6th (2002) and 7th (2009) edition of the AJCC
Cancer Staging Manual for PDAC. The 8th edition (October 2016)
marked the first major revision of the T- and N-classifications
(Table 1) and was made effective for patients diagnosed on or after
January 1st, 2018. The 8th edition separated the exocrine from
endocrine pancreatic tumors. In the present edition, the smallest
tumors of the T1 type (2 cm) now subcategorized based on size
(Fig. 1). These tumors are ‘minimally invasive’ and should have
better outcomes. Previously staging of T2 (>2  4 cm) and T3
(>4 cm) tumors included extra-pancreatic extension. This is diffi-
cult to define and, the T-categories are now size-based.
Further, the surgical resectability no longer define T4 tumors.
Instead, the categorization includes arterial involvement, which
holds an objective measure of the extent of invasion. Additionally,
the N-category split into N1 and N2, due to better prognostic
stratification based on the number of positive lymph nodes.le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Changes in definitions between the 7th and 8th edition of the TNM staging System.
Fig. 1. Illustration of current (AJCC 8th edition) T- and N-stage. Legend: Size-based
criteria for T-stages with sub-staging for T1 into T1a, T1b and T1c categories. N-stage is
based on numeric differences in metastatic lymph nodes, with 3 nodes as a cut-off.
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The TNM system is the only universal staging system in use, but
it has inherent limitations compared to other solid tumors, likely
due to the particular tumor biology of PDAC.For one, size is unreliable as a prognosticator in PDAC, as the
biological behavior even in small is far more unpredictable than in
most other solid tumors. Notably, in a large study of almost 59,000
patients from the SEER database, only 0.3% of patients had tumors
that were0.5 cm in size [3], e.g. T1a according toTNM 8th edition.
Despite the small size, almost one-third (31%) had distant metas-
tasis at time of diagnosis [3]. Clearly, this demonstrates the unre-
liable value of size as a prognosticator in PDAC and, moreover, point
to a systemic disease from the outset. This should be taken into
account in future attempts to refine staging.
Notably, ‘resectability’ is a subjective measurewith considerable
variations between institutions [4] in what constitutes inoperable
or non-resectable (Fig. 2), with different definitions for both
borderline and locally advanced PDAC in use. Increasingly, neo-
adjuvant therapy is used for resectable cancers, while still both
resectable and borderline-resectable may go to upfront surgery in
some centres. Evaluation of neoadjuvant therapy is unreliable,
which becomes a particular issue in borderline/locally advanced
cases, for which surgical exploration with multiple frozen sections
from tissue surrounding vessels being performed to expand re-
sections. For this particular group of patients, the current staging is
less useful, and a biological rather than anatomical definition of
resectability is called for [5]. Notably, when comparing pTNM
stages, the comparisonwill become increasinglymurkywith awide
range of treatments offered across clinical stages (Fig. 2).
Of note, the TNM-staging does not take into account the resection
status. Completeness of resection is of prognostic significance but is
Fig. 2. Depiction of the current treatment landscape of pancreatic cancer. Legend: Any given patient may be deemed inoperable at time of diagnosis or irresectable through
clinical (image-based) staging. Definitions for borderline/locally advanced cancers are floating, with variation in management. More effective systemic therapy (e.g. FOLFIRINOX) is
increasingly introduced in the pre-operative setting, with more resections offered after therapy, possibly influencing the pathological TNM-staging and interpretation of its
prognostic role. Better predictive and prognostic biomarkers of cancer biology are needed.
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criteria of the R-status. However, the International Study Group of
Pancreatic Surgery (ISGPS) endorsed the definition proposed by The
British Royal College of Pathologists [7]. In order to classify as R1, tu-
mor cells should be present within 1 mm from all seven designated
resection margins. The TNM 8th edition does not include resection
status, but considers themargin as positive if the tumor is at orwithin
1mm. However, it only takes account of themargin corresponding to
the superior mesenteric artery, while the seven margins for tumor
clearance in the pathology protocol. The rates of tumor involvement
therefore vary significantly in the literature, due to the differing def-
initions of positive microscopic margins. Meta-analysis of radical
resection rates shows ranges inR0-status from70 to 80%with a 0mm
margin, diminishing to 15e24%witha1mmmargin [8]. This in turn
affects the associated survival prognostics. Strobel et al. surveyed
patients after pancreaticoduodenectomy and adjuvant therapy, and
found median and 5-year survival rates independently associated, in
descending order, with a margin status of R0, R1 (<1 mm) or R1
(direct) [9]. Others have found that when Nþ disease is present, R-
status plays a lesser prognostic role [10].
Validation of the 8th edition
The changes in the 8th edition were mainly based on a multi-
institutional study from three centres in the United States [11]. Us-
ing the Surveillance, Epidemiology and End Results (SEER) database
(2004e2013) [12], the 8th edition proved discriminatory abilities
similar to thatof the7theditionbut allowed forafiner stratificationof
patientswith resected tumorsbasedonnodal involvement. The study
revealed similar survival rates for patients staged as IIA (T3N0M0) or
IIB (T1-3N1M0) until 20 months, before diverging. This suggests
lymphatic spread has a delayed impact on survival. However, based
on recurrence patterns investigated in the ESPAC-4 trial [13], there
was no survival difference in the pattern of recurrence, as either local
recurrence or distant metastasis, in terms of overall survival.
Further validation using data derived from patients withresected pancreatic cancer from Europe and the United States,
confirmed that the 8th edition over all provides a moderately
increased prognostic accuracy in surgically treated patients,
compared with the previous 7th edition [14]. The revised T-stages
were poorly associated with survival, especially in node-negative
patients. As a group, the node-negative patients pose the greatest
challenge in prognostication, yet, the new N stage was prognostic,
showing accurate discrimination of survival.
However, reports of conflicting findings exist. Schlitter et al.
found that all pT-stages, as defined in the 8th edition, showed
greatly improved discriminative powers with significant overall
differences in survival [15]. The latter study also found conflicting
outcome regarding node status, where the N1 and N2 categories of
the 8th edition resulted in no observed prognostic difference. This
in contrast to prior findings, where the finer stratification of node-
status appears to be prognostically significant [14].
Controversies
Primarily designed to assess the burden of disease, the TNM-
system currently fulfills several purposes, such as cancer surveil-
lance, deciding eligibility for clinical trials, and guiding treatment
and prognostication. However, it is evident that other factors,
including various aspects of tumor biology, molecular pathways
and biological mechanisms contribute to prognosis [16,17]. None of
these are currently included in the classification. Consequently it is
important to recognize the inherent limitations in the TNM-system
to predict patient outcomes [18].
After neoadjuvant treatment and subsequent surgical care, the
grade/degree of regression (equal to tumor response) can be
determined using the ypTNM staging (Fig. 1). No single tumor
regression grading system has been agreed on, although consensus
work is ongoing. In real-life, the clinican will have to rely on re-
staging by cross-sectional imaging after completed neoadjuvant
treatment. Again, large institutional variation exists inwhat defines
‘unresectable’ and ‘non-operable’. Also, it is rare to have complete
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most will have stable disease (40e60%) and some progress
(20e25%) during treatment [19,20]. As both clinical (image-based)
and pathological response is difficult to predict, biochemical
response by means of change in CA19-9 is used as a surrogate
biomarker that is related to neoadjuvant response and prognosis
[21e23].
Current and future biomarkers
Circulating tumor DNA (ctDNA) can be detected already when
pancreatic tumors are deemed resectable [24]. Further, a liquid
biopsy test detecting ctDNA for KRAS gene mutations, combined
with other protein markers, identified nearly two-thirds of
pancreatic tumors without evidence of distant metastasis, at the
time of surgery [25]. Similar results have been found when study-
ing exosomes [26]. Increasingly sensitive and specific detection
tools will conceivably result in non-invasive tests for early stage
pancreatic cancer [27].
Currently there is no consensus regarding the number or clas-
sification of molecular subtypes based on gene expression data in
PDAC, but agreement to at least two subtypes (so-called ‘basal-like’
and ‘classical’) have been reached [28]. These two have consider-
able differences in prognosis, with basal-like having more poorly
differentiated tumors and shorter overall survival compared to the
classical type [28]. Ongoing investigations into molecular alter-
ations (such as GATA expression) could identify potential predictive
biomarkers or help elucidate which tumor types would respond
better to either gemcitabine or FOLFIRINOX regimens [28].
Whether such biomarkers will become part of future staging
systems for PDAC, in order to incorporate tumor biology and cancer
behavior to personalized and guided treatment, remains to be
investigated. The need is evident, as resection currently is the only
curative approach, and early detection prior to metastasis is para-
mount for long-term survival.
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